Impulsivity and attentional bias as predictors of modafinil treatment outcome for retention and drug use in crack-cocaine dependent patients: Results of a randomised controlled trial
Background:
High impulsivity and attentional bias are common in cocaine-dependent patients and predict poor treatment outcomes. The pharmacological agent modafinil is studied for its cognitive-enhancing capacities and may therefore improve clinical outcomes in crack-cocaine dependent patients. In this study, we investigated first whether pre-treatment impulsivity and attentional bias predict treatment outcome; next whether the drug modafinil given as an add-on treatment to cognitive behavioural therapy (CBT) improves impulsivity and attentional bias; and last, whether changes in impulsivity and attentional bias are related to improvements in treatment outcome.
Methods:
Crack-cocaine dependent outpatients ( n = 65) were randomised to 12 weeks CBT plus modafinil (400 mg/day) or only CBT. Self-reported impulsivity was assessed at baseline using the Barratt Impulsiveness Scale. At baseline and Week 12, we assessed inhibitory control as a behavioural measure of impulsivity, in terms of cognitive interference (Stroop task) and response inhibition (‘stop-signal task’), and attentional bias with the addiction Stroop task. Clinical outcomes were CBT-retention and crack-cocaine use.
Results:
At baseline, self-reported impulsivity predicted better CBT-retention; low self-reported and behavioural impulsivity and attentional bias predicted less crack-cocaine use. Changes in cognitive performance were not modafinil-related, but most likely due to low adherence. Improvements in impulsivity or attentional bias were not associated with CBT-retention nor changes in crack-cocaine use.
Conclusions:
Baseline impulsivity and attentional bias predicted clinical outcomes in crack-cocaine dependent patients. There were no firm indications that modafinil reduced impulsivity nor attentional bias in this population. Future studies involving cognitive-enhancing medications should include strategies to optimise adherence, to be better able to evaluate their potential.
Top-30
Journals
|
1
2
|
|
|
BMC Psychiatry
2 publications, 8.7%
|
|
|
Addictive Behaviors
2 publications, 8.7%
|
|
|
Frontiers in Neuroscience
1 publication, 4.35%
|
|
|
Biomedicines
1 publication, 4.35%
|
|
|
Neuropsychopharmacology
1 publication, 4.35%
|
|
|
Journal of Neural Transmission
1 publication, 4.35%
|
|
|
Drug and Alcohol Dependence Reports
1 publication, 4.35%
|
|
|
Pharmacology Biochemistry and Behavior
1 publication, 4.35%
|
|
|
Developmental Cognitive Neuroscience
1 publication, 4.35%
|
|
|
Annals of the New York Academy of Sciences
1 publication, 4.35%
|
|
|
Addiction
1 publication, 4.35%
|
|
|
Current Addiction Reports
1 publication, 4.35%
|
|
|
Dialogues in Clinical Neuroscience
1 publication, 4.35%
|
|
|
Reviews in the Neurosciences
1 publication, 4.35%
|
|
|
Systematic Reviews
1 publication, 4.35%
|
|
|
Journal of ECT
1 publication, 4.35%
|
|
|
Adolescent Psychiatry
1 publication, 4.35%
|
|
|
American Psychologist
1 publication, 4.35%
|
|
|
International Journal of Mental Health and Addiction
1 publication, 4.35%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
7
|
|
|
Springer Nature
7 publications, 30.43%
|
|
|
Elsevier
6 publications, 26.09%
|
|
|
Wiley
2 publications, 8.7%
|
|
|
Frontiers Media S.A.
1 publication, 4.35%
|
|
|
MDPI
1 publication, 4.35%
|
|
|
Taylor & Francis
1 publication, 4.35%
|
|
|
Walter de Gruyter
1 publication, 4.35%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 4.35%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 4.35%
|
|
|
American Psychological Association (APA)
1 publication, 4.35%
|
|
|
1
2
3
4
5
6
7
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.